#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cushing's syndrome Clear cell papillary renal cell carcinoma Hodgkin's disease refractory Warm autoimmune haemolytic anaemia Philadelphia positive chronic myeloid leukaemia Acute promyelocytic leukaemia Oesophageal squamous cell carcinoma stage II Prader-Willi syndrome Trigeminal neuralgia Cystic fibrosis gastrointestinal disease Congenital disorder of glycosylation Infantile spasms B-cell lymphoma recurrent Epstein-Barr virus associated lymphoproliferative disorder Cerebral amyloid angiopathy More trials…

    Learn about Rare Diseases

    Ocular melanoma – Diagnostics Epidermolysis bullosa – Trials in Disease Combined immunodeficiency – Trials in Disease Hypereosinophilic syndrome – Treatment Pemphigus – Trials in Disease Retinoblastoma – Diagnostics Toxic epidermal necrolysis – Treatment Lymphangioma – Life with Disease Mastocytosis – Life with Disease Osteosarcoma metastatic – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ubamatamab Sodium Hyaluronate Bms-986408 Annamycin Nilutamide Ab-1002 LY3848575 Canis Familiaris (553) Mometasone Dexamethasone Phosphate Atidarsagene Autotemcel Olive Oil, Refined Autologous Microfat Zanubrutinib Lactose Monohydrate Lasofoxifene Ponsegromab Lutetium (177Lu) Edotreotide Bisoprolol Fumarate Nafarelin More therapies…

    Learn about Your Condition

    Immunodeficiency Colorectal cancer metastatic Heparin resistance Large cell lung cancer Tympanic membrane hyperaemia Anxiety disorder Skin wrinkling Tooth loss Metastasis HER2 negative breast cancer Cartilage injury Raynaud's phenomenon Interstitial lung disease Andersen-Tawil syndrome Acute on chronic liver failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Theageneio Cancer Hospital

Theageneio Cancer Hospital

Simeonidi Alex 2, Thessaloniki, 546 39, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Belantamab Mafodotin
    • Dexamethasone
    • Dexamethasone Ph. Eur.
    Belgium Bulgaria France Germany Greece Hungary +4

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Goserelin
    • Triptorelin
    • Leuprorelin Acetate
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Datopotamab Deruxtecan
    • Durvalumab
    Belgium Denmark France Germany Greece Italy +2

  • Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer recurrent
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Ipilimumab
    France Greece Italy Poland Romania

  • Study of belantamab mafodotin combined with pomalidomide, dexamethasone, and daratumumab in patients with relapsed/refractory multiple myeloma who previously had 1-3 treatments and are lenalidomide resistant

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Belantamab Mafodotin
    • Daratumumab
    • Dexamethasone
    Greece

  • Study of Isatuximab with drug combination for newly diagnosed multiple myeloma patients with severe kidney problems

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Bortezomib
    • Cyclophosphamide Monohydrate
    • Dexamethasone
    Greece

  • Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pembrolizumab
    Croatia Greece Lithuania Poland Romania Spain

  • Study of Isatuximab, Pomalidomide and Dexamethasone combination for multiple myeloma patients who previously received Lenalidomide and Proteasome Inhibitor therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dexamethasone
    • Isatuximab
    • Pomalidomide
    Greece

  • Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Savolitinib
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria France Germany Greece +3

  • Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Iberdomide
    • Bortezomib
    • Daratumumab
    Austria Belgium Czechia Denmark Finland France +10
Previous Page
1 … 3 4 5 6 7 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!